Syros | Jotup

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Retrieved on:

Tuesday, April 9, 2024

Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with venetoclax and azacitidine for the treatment of newly diagnosed AML patients with RARA gene overexpression.

Key Points:

Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with venetoclax and azacitidine for the treatment of newly diagnosed AML patients with RARA gene overexpression.
“We are pleased to receive Fast Track designation for tamibarotene for the treatment of AML.
Syros is evaluating tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit AML patients with RARA overexpression in the ongoing SELECT-AML-1 Phase 2 trial.
In January 2023, the FDA granted Fast Track Designation to tamibarotene for the treatment of HR-MDS patients with RARA overexpression.

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Retrieved on:

Wednesday, March 20, 2024

Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, ID, Webcast, Syros, Bone marrow

ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

Key Points:

ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (international) and refer to conference ID 21905455.
A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .
An archived replay of the webcast will be available for approximately 30 days following the call.

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Retrieved on:

Tuesday, February 27, 2024

Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Bone marrow, Webcast, Syros, Conference

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference.

Key Points:

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference.
Management will also be available for one-on-one meetings.
Details are as follows:
A live webcast of the panel discussion will be available on the Investors & Media section of the Syros website at www.syros.com .
An archived replay of the webcast will be available for approximately 30 days following the live event.

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Retrieved on:

Monday, January 8, 2024

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, RARA, Aplastic anemia, Bone marrow, New Drug Application, Syros, Azacitidine, Venetoclax, Patient, Acute myeloid leukemia, AML, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.

Key Points:

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.
In addition, we closed an approximately $45.0 million equity financing, providing us additional capital to advance the development of tamibarotene.
By the middle of the fourth quarter of 2024, we expect to report pivotal data from the SELECT-MDS-1 Phase 3 clinical trial.
Syros is also evaluating tamibarotene in combination with venetoclax and azacitidine in newly diagnosed unfit AML patients with RARA overexpression.

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Tuesday, December 19, 2023

Biotechnology, Pharmaceutical, Health, Oncology, Telephone, Lexington Avenue, Sale, Nicollet Mall, Attention, Bone marrow, Syros, Prospectus, Security (finance)

All shares and pre-funded warrants are being offered by Syros.

Key Points:

All shares and pre-funded warrants are being offered by Syros.
Closing of the offering is expected to occur on or about December 21, 2023, subject to customary closing conditions.
The offering will be made only by means of the prospectus and prospectus supplement that form a part of the registration statement.
The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC.

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Retrieved on:

Wednesday, December 6, 2023

“These data highlight the potential of tamibarotene to be a cornerstone therapy for newly diagnosed, unfit AML patients with RARA overexpression, further demonstrating its differentiated product profile and validating our biologically targeted approach,” said David A. Roth, M.D., Chief Medical Officer of Syros. “These results -- the first from a randomized, controlled study -- demonstrate the potential impact of adding tamibarotene to the standard-of-care, venetoclax and azacitidine and, importantly, are consistent with prior experience. Across multiple clinical trials, we have observed tamibarotene’s ability to rapidly deliver clinically relevant activity, with a well-tolerated safety profile, including in a combination setting. We look forward to advancing our comprehensive clinical development program for tamibarotene, with additional data from SELECT-AML-1 and pivotal complete response data from our SELECT-MDS-1 trial in higher-risk myelodysplastic syndrome with RARA overexpression expected next year, as we work to deliver profound benefit to patients with hematologic malignancies.”

Key Points:

“These results -- the first from a randomized, controlled study -- demonstrate the potential impact of adding tamibarotene to the standard-of-care, venetoclax and azacitidine and, importantly, are consistent with prior experience.
Across multiple clinical trials, we have observed tamibarotene’s ability to rapidly deliver clinically relevant activity, with a well-tolerated safety profile, including in a combination setting.
The trial is also evaluating the triplet regimen as a salvage strategy in patients in the control arm who do not respond to venetoclax and azacitidine.
Syros is also evaluating tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression.

Syros to Participate in Upcoming Investor Conferences

Retrieved on:

Tuesday, November 21, 2023

Oncology, Health, Communications, Genetics, Pharmaceutical, Biotechnology, Public Relations, Investor Relations, Webcast, Bone marrow, Syros, Madison Avenue

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences.

Key Points:

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences.
Management will also be available for one-on-one meetings.
Details are as follows:
Location: The Lotte New York Palace, 455 Madison Ave, New York, NY
To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com .
An archived replay of each webcast will be available for approximately 30 days following each presentation.

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on:

Tuesday, November 14, 2023

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points:

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
In October 2023, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., effective December 1, 2023.
General and administrative expenses were $7.8 million for the third quarter of 2023, as compared to $8.1 million for the third quarter of 2022.
ET to discuss these third quarter 2023 financial results and provide a corporate update.

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Retrieved on:

Tuesday, November 7, 2023

Health, Pharmaceutical, Bone marrow, ID, Syros, Webcast, Pharmaceutical industry, Broadcasting, Cryptocurrency

ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update.

Key Points:

ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update.
To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (international) and refer to conference ID 83649711.
A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .
An archived replay of the webcast will be available for approximately 30 days following the call.

Syra Health Announces the Launch of CarePlus, the Company's Electronic Medical Record System

Retrieved on:

Thursday, October 19, 2023

EMR, Syros, Digital health, Electronic health record

CARMEL, Ind., Oct. 19, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the launch of CarePlus, its own Electronic Medical Record (EMR) system designed specifically for small to mid-sized healthcare organizations.

Key Points:

CARMEL, Ind., Oct. 19, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company with a mission to improve healthcare by providing innovative services and technology solutions, announced today the launch of CarePlus, its own Electronic Medical Record (EMR) system designed specifically for small to mid-sized healthcare organizations.
CarePlus is an easy-to-use, secure, and scalable platform that allows for streamlining clinical workflows and integrating telehealth.
"We listened to what healthcare providers were telling us they wanted in their EMR system," said Sandeep Allam, Executive Chairman, President, and Digital Health Leader, Syra Health.
"Our Syra Health developers have created CarePlus that solves a common complaint heard across the healthcare industry about EMR Systems," said Dr. Deepika Vuppalanchi, CEO, Syra Health.